Paris-based DNA engineering specialist Cellectis SA has granted GlaxoSmithKline plc a worldwide, non-exclusive sub-license to its gene targeting platform technology.
The technology is used to precisely substitute, delete or add genetic sequences at a chosen location in a genome, and is used in particular to generate mouse models of human disease.
The technology was invented at the Institut Pasteur in Paris. The licence gives GlaxoSmithKline the right to the technology for in vitro and in vivo modifications. Financial terms and conditions of the agreement were not disclosed.